167 related articles for article (PubMed ID: 32972820)
21. Prognostic Value of Hepatocyte Growth Factor Receptor Expression in Patients with Perihilar Cholangiocarcinoma.
Watanabe H; Yokoyama Y; Kokuryo T; Ebata T; Igami T; Sugawara G; Mizuno T; Shimoyama Y; Nagino M
Ann Surg Oncol; 2015 Jul; 22(7):2235-42. PubMed ID: 25586241
[TBL] [Abstract][Full Text] [Related]
22. Multiple pulmonary adenomas in the lung of transgenic mice overexpressing the RON receptor tyrosine kinase. Recepteur d'origine nantais.
Chen YQ; Zhou YQ; Fu LH; Wang D; Wang MH
Carcinogenesis; 2002 Nov; 23(11):1811-9. PubMed ID: 12419829
[TBL] [Abstract][Full Text] [Related]
23. A missing link between RON expression and oncological outcomes in resected left-sided pancreatic cancer.
Han DH; Kang CM; Lee SW; Hwang HK; Lee WJ
Oncol Lett; 2017 Oct; 14(4):4225-4230. PubMed ID: 28943931
[TBL] [Abstract][Full Text] [Related]
24. RON, a tyrosine kinase receptor involved in tumor progression and metastasis.
Camp ER; Liu W; Fan F; Yang A; Somcio R; Ellis LM
Ann Surg Oncol; 2005 Apr; 12(4):273-81. PubMed ID: 15827676
[TBL] [Abstract][Full Text] [Related]
25. Clinicopathological and prognostic values of fibronectin and integrin αvβ3 expression in primary osteosarcoma.
Shi K; Wang SL; Shen B; Yu FQ; Weng DF; Lin JH
World J Surg Oncol; 2019 Jan; 17(1):23. PubMed ID: 30691475
[TBL] [Abstract][Full Text] [Related]
26. Macrophage stimulating protein preserves blood brain barrier integrity after intracerebral hemorrhage through recepteur d'origine nantais dependent GAB1/Src/β-catenin pathway activation in a mouse model.
Lu T; Wang Z; Prativa S; Xu Y; Wang T; Zhang Y; Yu L; Xu N; Tang J; You W; Chen G; Zhang JH
J Neurochem; 2019 Jan; 148(1):114-126. PubMed ID: 30380151
[TBL] [Abstract][Full Text] [Related]
27. Expression of the recepteur d'originenantais receptor tyrosine kinase in non-small cell lung cancer and its clinical significance.
Han WL; Li WD; Hu J; Rusidanmu A; Chen LF; Shen L; Zheng SS
Chin Med J (Engl); 2012 Mar; 125(6):1110-4. PubMed ID: 22613539
[TBL] [Abstract][Full Text] [Related]
28. Small interfering RNA targeting of Recepteur d'Origine Nantais induces apoptosis via modulation of nuclear factor-kappaB and Bcl-2 family in gastric cancer cells.
Park JS; Park JH; Lee S; Joo YE; Jung YD
Oncol Rep; 2010 Sep; 24(3):709-14. PubMed ID: 20664977
[TBL] [Abstract][Full Text] [Related]
29. Aberrant RON and MET Co-overexpression as Novel Prognostic Biomarkers of Shortened Patient Survival and Therapeutic Targets of Tyrosine Kinase Inhibitors in Pancreatic Cancer.
Hu CY; Xu XM; Hong B; Wu ZG; Qian Y; Weng TH; Liu YZ; Tang TM; Wang MH; Yao HP
Front Oncol; 2019; 9():1377. PubMed ID: 31867280
[TBL] [Abstract][Full Text] [Related]
30. Clinicopathological and prognostic value of NADPH oxidase 2 (NOX2) in primary osteosarcoma.
Lin RJ; Huang Z; Wang SL; Chen H; Wei HX; Shen RK; Yang LY; Lin JH
J Orthop Sci; 2021 May; 26(3):466-472. PubMed ID: 32402505
[TBL] [Abstract][Full Text] [Related]
31. Structural basis for the binding specificity of human Recepteur d'Origine Nantais (RON) receptor tyrosine kinase to macrophage-stimulating protein.
Chao KL; Gorlatova NV; Eisenstein E; Herzberg O
J Biol Chem; 2014 Oct; 289(43):29948-60. PubMed ID: 25193665
[TBL] [Abstract][Full Text] [Related]
32. Chrysin inhibits cell invasion by inhibition of Recepteur d'origine Nantais via suppressing early growth response-1 and NF-κB transcription factor activities in gastric cancer cells.
Xia Y; Lian S; Khoi PN; Yoon HJ; Han JY; Chay KO; Kim KK; Jung YD
Int J Oncol; 2015 Apr; 46(4):1835-43. PubMed ID: 25625479
[TBL] [Abstract][Full Text] [Related]
33. Receptor tyrosine kinase, RON, promotes tumor progression by regulating EMT and the MAPK signaling pathway in human oral squamous cell carcinoma.
Kim SA; Lee KH; Lee DH; Lee JK; Lim SC; Joo YE; Chung IJ; Noh MG; Yoon TM
Int J Oncol; 2019 Aug; 55(2):513-526. PubMed ID: 31268163
[TBL] [Abstract][Full Text] [Related]
34. Oncogenesis of RON receptor tyrosine kinase: a molecular target for malignant epithelial cancers.
Wang MH; Yao HP; Zhou YQ
Acta Pharmacol Sin; 2006 Jun; 27(6):641-50. PubMed ID: 16723080
[TBL] [Abstract][Full Text] [Related]
35. RON and MET Co-overexpression Are Significant Pathological Characteristics of Poor Survival and Therapeutic Targets of Tyrosine Kinase Inhibitors in Triple-Negative Breast Cancer.
Weng TH; Yao MY; Xu XM; Hu CY; Yao SH; Liu YZ; Wu ZG; Tang TM; Fu PF; Wang MH; Yao HP
Cancer Res Treat; 2020 Jul; 52(3):973-986. PubMed ID: 32324988
[TBL] [Abstract][Full Text] [Related]
36. RON is associated with tumor progression via the inhibition of apoptosis and cell cycle arrest in human gastric cancer.
Song YA; Park YL; Kim KY; Myung E; Chung CY; Cho SB; Lee WS; Jung YD; Kweon SS; Joo YE
Pathol Int; 2012 Feb; 62(2):127-36. PubMed ID: 22243783
[TBL] [Abstract][Full Text] [Related]
37. Novel splicing variants of recepteur d'origine nantais (RON) tyrosine kinase involving exons 15-19 in lung cancer.
Krishnaswamy S; Mohammed AK; Amer OE; Tripathi G; Alokail MS; Al-Daghri NM
Lung Cancer; 2016 Feb; 92():41-6. PubMed ID: 26775595
[TBL] [Abstract][Full Text] [Related]
38. RON alternative splicing regulation in primary ovarian cancer.
Mayer S; Hirschfeld M; Jaeger M; Pies S; Iborra S; Erbes T; Stickeler E
Oncol Rep; 2015 Jul; 34(1):423-30. PubMed ID: 25997828
[TBL] [Abstract][Full Text] [Related]
39. The RON receptor tyrosine kinase promotes MSP-independent cell spreading and survival in breast epithelial cells.
Feres KJ; Ischenko I; Hayman MJ
Oncogene; 2009 Jan; 28(2):279-88. PubMed ID: 18836480
[TBL] [Abstract][Full Text] [Related]
40. Oncogenic and invasive potentials of human macrophage-stimulating protein receptor, the RON receptor tyrosine kinase.
Wang MH; Wang D; Chen YQ
Carcinogenesis; 2003 Aug; 24(8):1291-300. PubMed ID: 12807733
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
